<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>38(1)</volume><submitter>Alidjanov JF</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>To reassess the diagnostic values of the "draft" guidelines for the clinical diagnosis of acute uncomplicated cystitis (AC), recently proposed by US Food and Drug Administration (FDA) and European Medicines Agency (EMA).&lt;h4>Methods&lt;/h4>The data of 517 female respondents (patients with acute cystitis and controls) derived from the e-USQOLAT database were analyzed and used for the validation of proposed "draft" guidelines of FDA and EMA, compared to the Acute Cystitis Symptom Score (ACSS) questionnaire. The diagnostic values of the proposals concerning signs, symptoms and their severity were assessed and compared.&lt;h4>Results&lt;/h4>The six "typical" symptoms of the ACSS were strongly associated with the diagnosis of AC. The number of positive "typical" symptoms differed signific</pubmed_abstract><journal>World journal of urology</journal><pagination>63-72</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6954149</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women.</pubmed_title><pmcid>PMC6954149</pmcid><pubmed_authors>Pilatz A</pubmed_authors><pubmed_authors>Tenke P</pubmed_authors><pubmed_authors>Zamuddinov M</pubmed_authors><pubmed_authors>Alidjanov JF</pubmed_authors><pubmed_authors>Naber KG</pubmed_authors><pubmed_authors>Magyar A</pubmed_authors><pubmed_authors>Wagenlehner FM</pubmed_authors><pubmed_authors>Radzhabov A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women.</name><description>&lt;h4>Purpose&lt;/h4>To reassess the diagnostic values of the "draft" guidelines for the clinical diagnosis of acute uncomplicated cystitis (AC), recently proposed by US Food and Drug Administration (FDA) and European Medicines Agency (EMA).&lt;h4>Methods&lt;/h4>The data of 517 female respondents (patients with acute cystitis and controls) derived from the e-USQOLAT database were analyzed and used for the validation of proposed "draft" guidelines of FDA and EMA, compared to the Acute Cystitis Symptom Score (ACSS) questionnaire. The diagnostic values of the proposals concerning signs, symptoms and their severity were assessed and compared.&lt;h4>Results&lt;/h4>The six "typical" symptoms of the ACSS were strongly associated with the diagnosis of AC. The number of positive "typical" symptoms differed signific</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jan</publication><modification>2025-04-04T11:06:02.315Z</modification><creation>2020-05-22T08:15:52Z</creation></dates><accession>S-EPMC6954149</accession><cross_references><pubmed>31004204</pubmed><doi>10.1007/s00345-019-02761-3</doi></cross_references></HashMap>